Article

Developments in clinical cell therapy.

National Institutes of Health, Bethesda, Maryland, USA.
Cytotherapy (Impact Factor: 3.06). 05/2010; 12(3):425-8. DOI: 10.3109/14653240903511952
Source: PubMed

ABSTRACT Immunotherapy has become an important part of hematopoietic stem cell (HSC) transplantation and cancer therapy. Regenerative and reparative properties of somatic cell-based therapies hold tremendous promise for repairing injured tissue, preventing and reversing damage to organs, and restoring balance to compromised immune systems. The principles and practices of the diverse aspects of immune therapy for cancer, HSC transplantation and regenerative medicine have many commonalities. This meeting report summarizes a workshop sponsored by the National Heart, Lung and Blood Institute (NHLBI) and Production Assistance for Cellular Therapies (PACT), held on 23-24 April 2009 at the National Institutes of Health (NIH, USA). A series of scientific sessions and speakers highlighted key aspects of the latest scientific, clinical and technologic developments in cell therapy, involving a unique set of cell products with a special emphasis on converging concepts in these fields.

0 Bookmarks
 · 
107 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Advanced therapy medicinal products (ATMP) represents a new class of medicinal products, which include - amongst others - somatic cell and gene therapies. As the final product is intended for administration into humans, manufacturers of ATMPs are obligated to apply good manufacturing practice (GMP) standards within their processes. Reaching and maintaining such standards is cost intensive and requires sophisticated manufacturing facilities. As a result, academic researchers who are developing these novel therapeutic approaches are facing new technological and financial challenges. In order to bring more commercially accessible therapies to patients and demonstrate efficient manufacturing technologies, we established the clean-room technology assessment technique (CTAT). CTAT comprises several tools to identify and assign a reliable monetary value to the different operational processes. The model also serves as a guideline for optimizing the operation of an academic GMP facility.
    First Edition edited by Mohamed Abou-El-Enein, 09/2014; Südwestdeutscher Verlag für Hochschulschriften., ISBN: 978-3-8381-3865-7
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CIK cells therapy has been evaluated as an adoptive cell immunotherapy for cancer patients, but there still have not been any standardized systems for evaluating the antitumor efficacy yet. The WHO and RECIST criteria have already been established for a few years but not sufficient to fully characterize the activity of immunotherapy. Based on these two criteria, the irRC was proposed for evaluating the efficacy of immunotherapy. A variety of bioassays for immune monitoring including the specific and non-specific methods, have been established. We recommend detect levels of various immunocytes, immune molecules and soluble molecules to find the correlations among them and clinicopathological characteristics to establish criteria for immunological classification. We also recommend a paradigm shift for the oncologists in the evaluation of immune therapies to ensure assessment of activity based on clinically relevant criteria and time points.
    Journal of Translational Medicine 08/2014; 12(1):215. DOI:10.1186/s12967-014-0215-0 · 3.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cytokine-induced killer (CIK) cells are ex vivo generated heterogeneous NK-like T-lymphocytes, which have anti-tumor effects in vitro and in vivo. This present study was conducted to evaluate the effects of autologous CIK cell immunotherapy on the prognosis of colorectal cancer patients. Progression-free survival (PFS), overall survival (OS) and immune cells were assessed. We found that the percentages of CD8+, CD3+ CD56+, CD3− CD56+ cell subsets were significantly increased from 19.7 ± 6.3%, 13.8 ± 7.9%, 1.0 ± 1.2% to 35.8 ± 11.6% (P < 0.001), 20.9 ± 12.5 (P < 0.001), 14.4 ± 9.5% (P < 0.001), respectively in the CIK group after 14 days of incubation. The median PFS and median OS in the CIK group were 25.8 months and 41.3 months respectively, while 12.0 months and 30.8 months in the control group. The PFS and OS curves of the CIK group and control group indicated that there were also statistically differences between two groups in PFS (log-rank, P = 0.01) and OS (log-rank, P = 0.037). Our results indicate that CIK cell immunotherapy in combination with chemotherapy can reduce the recurrence rate and promote the survival time of patients with colorectal cancer.
    Biomedecine [?] Pharmacotherapy 07/2014; 68(6). DOI:10.1016/j.biopha.2014.07.010 · 2.11 Impact Factor

Full-text (2 Sources)

Download
32 Downloads
Available from
May 23, 2014